1 / 11

Masayuki Saijo, M.D., Ph. D Department of Virology 1, National Institute of Infectious Diseases

Highly containment laboratory in the National Institute of Infectious Diseases, Tokyo, Japan: activities, circumstances, and future challenges. Masayuki Saijo, M.D., Ph. D Department of Virology 1, National Institute of Infectious Diseases. Current situation of BSL-4 facilities in NIID.

conor
Télécharger la présentation

Masayuki Saijo, M.D., Ph. D Department of Virology 1, National Institute of Infectious Diseases

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Highly containment laboratory in the National Institute of Infectious Diseases, Tokyo, Japan: activities, circumstances, and future challenges Masayuki Saijo, M.D., Ph. D Department of Virology 1, National Institute of Infectious Diseases

  2. Current situation of BSL-4 facilities in NIID • Glove box-type BSL-4 facility was constructed and installed in the NIID (Murayama annex) in early 1980’s. • Role of the Special Pathogens Laboratory in Dept Virol 1, NIID • Basic science for viral hemorrhagic fevers and other emerging virus infections • Quality Control of Smallpox vaccine • Preparedness for the risk of viral • The BSL-4 facility has not yet operated as BSL-4 facility but as BSL-3 laboratories. • Opposition by the residents and local municipality to the operation of the facility as BSL-4

  3. Japanese Infectious Control Law • Ebolavirus, Marburg virus, Crimean-Congo hemorrhagic fever virus, Lassa virus, South American hemorrhagic fever viruses, Variola virus, and Yersinia pestis are defined as BSL-4 pathogens in the JIDC law. • The law restricts importation, possession, transportation, transfer and sterilization. • Furthermore, the law tightened the control of animal importation.

  4. Research Activities in Highly Containment Laboratory • Development of diagnostic systems for Hemorrhagic fever viruses (Ebola, Marburg, CCHF, Lassa, etc) -mission • Monkeypox virus infections • Pathogenesis, diagnostics, immunology • SARS • Diagnostics, Vaccine development, Animal model development, and Pathogenesis • Efficacy assessment of a newly developed highly pathogenic avian influenza vaccine using nonhuman primate models • Efficacy assessment of a highly attenuated smallpox vaccine, LC16m8, using nonhuman primate models • Induction of protective efficacy, Post-exposure vaccination, long-term efficacy

  5. Recombinant NP-based diagnosis of CCHF Tang Q, et al. A patient with Crimean-Congo hemorrhagic fever diagnosed with recombinant nucleoprotein-based antibody detection systems. Clin Diag Lab Immunol 10:489-491, 2003

  6. Clinical course Patient: 28-year old shepherd in the Xinjiang Uygur Autonomous Region in 2001 Symptoms： fever, unconsciousness, hemorrhage (nostril, gingiva, rectum) Laboratory findings： anemia (Hb 10.0 g/dl), thrombocytopenia (8.41010/L), elevated transaminases (ALT, AST, LDH;173, 216, 268 U/L), hyperbilirubinamia, hypoalbuminamia

  7. Virological test results on CCHF virus infection Days from onset 1 5 9 (Days) RT-PCR (nested) + - - Ag-capture ELISA 0.381 0.007 0.000 (OD405) IgG-ELISA (1:100) 0.075 0.924 1.882 (OD405) (1:400) 0.031 0.486 0.972 IgM-capture ELISA (OD405) (1:100) 0.020 2.692 2.711 (1:400) 0.040 1.606 2.001 1 5 9 NC 300 200

  8. International collaborations • US CDC (Atlanta, GA) • Ebola, Marburg, Smallpox (vaccine study) • INSERM (Lyon, France) • Lassa, Marburg • China CDC (Beijing, China) • Crimean-Congo hemorrhagic fever • RITM (Manila, the Philippines) • Reston Ebolavirus • University of Maiduguri (Maiduguri, Nigeria) • Hemorrhagic fevers • University of Ghana (Acura, Ghana) • Hemorrhagic fevers

  9. Future challenges-key player- • Need to operate the facility as BSL-4 laboratory in order to prepare the possible outbreak of highly pathogenic hemorrhagic fever virus infections and other novel emerging infections not only in Japan, but also in the other part of the world. • Need to play an important role to combat the highly pathogenic infections in collaboration with the key partners in the world.

  10. Future challenges-operation- • Requirement of mutual understandings on the safety and operation risks between the NIID and communities. • Requirement of mutual collaboration to the operation of BSL-4 facilities between NIID and the Ministry of Health, Labor, and Welfare of Japan.

  11. Action plans • Mutual understanding • Periodical seminars on infections diseases to the residents in communities • Establishment of Safety committee between the local municipalities and the NIID • Others • Mutual collaboration • Between the NIID and MHLW • Between the NIID and Ministry of Education, Culture, Science, and Technology • Between the NIID and Academics

More Related